NCT03612232View on ClinicalTrials.gov

Cabozantinib in Advanced Adrenocortical Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

June 4, 2019

Primary Completion Date

December 31, 2024

Study Completion Date

April 30, 2025

Conditions
Adrenocortical Carcinoma
Interventions
DRUG

Cabozantinib-s-malate

oral cabozantinib-S-malate 60 mg as a daily single oral dose continuously

Trial Locations (2)

80336

University Hospital Munich, Department of Internal Medicine IV, München

97080

University Hospital Würzburg, Würzburg

All Listed Sponsors
lead

Wuerzburg University Hospital

OTHER